Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

Cited In for PubMed (Select 18525265)

1.

High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau.

Jespersen S, Tolstrup M, Hønge BL, Medina C, Té Dda S, Ellermann-Eriksen S, Østergaard L, Wejse C, Laursen AL; Bissau HIV cohort study group.

Virol J. 2015 Mar 11;12:41. doi: 10.1186/s12985-015-0273-9.

2.

Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations.

Jespersen S, Hønge BL, Oliveira I, Medina C, da Silva Té D, Correia FG, da Silva ZJ, Erikstrup C, Østergaard L, Laursen AL, Wejse C; the; Bissau HIV cohort study group.

Bull World Health Organ. 2014 Dec 1;92(12):909-14. doi: 10.2471/BLT.14.135749. Epub 2014 Sep 26.

3.

Prevalence of community-acquired bacteraemia in Guinea-Bissau: an observational study.

Isendahl J, Manjuba C, Rodrigues A, Xu W, Henriques-Normark B, Giske CG, Nauclér P.

BMC Infect Dis. 2014 Dec 20;14:3859. doi: 10.1186/s12879-014-0715-9.

4.

A modular system to evaluate the efficacy of protease inhibitors against HIV-2.

Mahdi M, Matúz K, Tóth F, Tőzsér J.

PLoS One. 2014 Nov 24;9(11):e113221. doi: 10.1371/journal.pone.0113221. eCollection 2014.

5.

Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Ekouevi DK, Tchounga BK, Coffie PA, Tegbe J, Anderson AM, Gottlieb GS, Vitoria M, Dabis F, Eholie SP.

BMC Infect Dis. 2014 Aug 26;14:461. doi: 10.1186/1471-2334-14-461. Review.

6.

Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.

Hønge BL, Jespersen S, Medina C, Té Dda S, da Silva ZJ, Lewin S, Østergaard L, Erikstrup C, Wejse C, Laursen AL, Krarup H; Bissau HIV cohort study group.

PLoS One. 2014 Jun 10;9(6):e99971. doi: 10.1371/journal.pone.0099971. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0119246.

7.

Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival.

Aaby P, Martins CL, Garly ML, Andersen A, Fisker AB, Claesson MH, Ravn H, Rodrigues A, Whittle HC, Benn CS.

Clin Infect Dis. 2014 Aug 15;59(4):484-92. doi: 10.1093/cid/ciu354. Epub 2014 May 14.

8.

Trends and determinants of mortality in women of reproductive age in rural Guinea-Bissau, West Africa--a cohort study.

Mane M, Fisker AB, Ravn H, Aaby P, Rodrigues A.

BMC Womens Health. 2013 Dec 5;13:48. doi: 10.1186/1472-6874-13-48.

9.

Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study.

Hønge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, da Silva ZJ, Ostergaard L, Laursen AL, Wejse C; Bissau HIV cohort study group.

BMJ Open. 2013 Oct 25;3(10):e003499. doi: 10.1136/bmjopen-2013-003499.

10.

Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.

Ekouevi DK, Balestre E, Coffie PA, Minta D, Messou E, Sawadogo A, Minga A, Sow PS, Bissagnene E, Eholie SP, Gottlieb GS, Dabis F; IeDEA West Africa collaboration, Zannou DM, Ahouada C, Akakpo J, Ahomadegbé C, Bashi J, Gougounon-Houéto A, Azon-Kouanou A, Houngbé F, Koumakpaï S, Alihonou F, d'Almeida M, Hodonou I, Hounhoui G, Sagbo G, Tossa-Bagnan L, Adjide H, Drabo J, Bognounou R, Dienderé A, Traore E, Zoungrana L, Zerbo B, Sawadogo AB, Zoungrana J, Héma A, Soré I, Bado G, Tapsoba A, Yé D, Kouéta F, Ouedraogo S, Ouédraogo R, Hiembo W, Gansonré M, Messou E, Gnokoro JC, Koné M, Kouakou GM, Bosse CA, Brou K, Assi AI, Chenal H, Hawerlander D, Soppi F, Minga A, Abo Y, Bomisso G, Eholié SP, Amego MD, Andavi V, Diallo Z, Ello F, Tanon AK, Koule SO, Anzan KC, Guehi C, Aka EA, Issouf KL, Kouakou JC, N'gbeche MS, Touré P, Avit-Edi D, Kouakou K, Moh M, Yao VA, Folquet MA, Dainguy ME, Kouakou C, Méa-Assande VT, Oka-Berete G, Zobo N, Acquah P, Kokora MB, Eboua TF, Timité-Konan M, Ahoussou LD, Assouan JK, Sami MF, Kouadio C, Renner L, Goka B, Welbeck J, Sackey A, Owiafe SN, Wejse C, Silva ZJ, Paulo J, Rodrigues A, da Silva D, Medina C, Oliviera-Souto I, Ostergaard L, Laursen A, Sodemann M, Aaby P, Fomsgaard A, Erikstrup C, Eugen-Olsen J, Maïga MY, Diakité FF, Kalle A, Katile D, Traore HA, Minta D, Cissé T, Dembelé M, Doumbia M, Fomba M, Kaya AS, Traoré AM, Traoré H, Toure AA, Dicko F, Sylla M, Berthé A, Traoré HC, Koïta A, Koné N, N'diaye C, Coulibaly ST, Traoré M, Traoré N, Charurat M, Ajayi S, Dapiap S, Otu, Igbinoba F, Benson O, Adebamowo C, James J, Obaseki, Osakede P, Olasode J, Sow PS, Diop B, Manga NM, Tine JM, Signate Sy H, Ba A, Diagne A, Dior H, Faye M, Gueye RD, Mbaye AD, Patassi A, Kotosso A, Kariyare BG, Gbadamassi G, Komi A, Mensah-Zukong KE, Pakpame P, Lawson-Evi AK, Atakouma Y, Takassi E, Djeha A, Ephoévi-Gah A, Djibril SE, Dabis F, Bissagnene E, Arrivé E, Coffie P, Ekouevi D, Jaquet A, Leroy V, Lewden C, Sasco A, Azani JC, Allou G, Balestre E, Bohossou F, Karcher S, Gonsan JM, Carrou JL, Lenaud S, Nchot C, Malateste K, Yao AR, Siloué B, Clouet G, Djetouan H, Doring A, Kouakou A, Rabourdin E, Rivenc J, Anglaret X, Ba B, Essanin JB, Ciaranello A, Datté S, Desmonde S, Diby JS, Gottlieb GS, Horo AG, Kangah SN, Malvy D, Meless D, Mounkaila-Harouna A, Ndondoki C, Shiboski C, Thiébaut R, Pac-Ci, Abidjan.

PLoS One. 2013 Jun 18;8(6):e66135. Print 2013.

11.

High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.

Takeuchi JS, Perche B, Migraine J, Mercier-Delarue S, Ponscarme D, Simon F, Clavel F, Labrosse B.

Retrovirology. 2013 May 6;10:50. doi: 10.1186/1742-4690-10-50.

12.

Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study.

Gomes VF, Andersen A, Lemvik G, Wejse C, Oliveira I, Vieira FJ, Carlos LJ, Vieira Cda S, Aaby P, Gustafson P.

BMJ Open. 2013 Mar 26;3(3). pii: e001545. doi: 10.1136/bmjopen-2012-001545.

13.

The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals.

Yu H, Usmani SM, Borch A, Krämer J, Stürzel CM, Khalid M, Li X, Krnavek D, van der Ende ME, Osterhaus AD, Gruters RA, Kirchhoff F.

Retrovirology. 2013 Mar 5;10:27. doi: 10.1186/1742-4690-10-27.

14.

Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1.

Gottlieb GS.

AIDS. 2013 Jan 2;27(1):135-7. doi: 10.1097/QAD.0b013e32835a11a4. No abstract available.

15.

Trends of HIV-1, HIV-2 and dual infection in women attending outpatient clinics in Senegal, 1990-2009.

Heitzinger K, Sow PS, Dia Badiane NM, Gottlieb GS, N'Doye I, Toure M, Kiviat NB, Hawes SE; University of Washington-Dakar HIV and Cervical Cancer Study Group.

Int J STD AIDS. 2012 Oct;23(10):710-6. doi: 10.1258/ijsa.2012.011219.

16.

Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Özkaya Şahin G, Holmgren B, Sheik-Khalil E, da Silva Z, Nielsen J, Nowroozalizadeh S, Månsson F, Norrgren H, Aaby P, Fenyö EM, Jansson M.

J Virol. 2013 Jan;87(1):273-81. doi: 10.1128/JVI.01640-12. Epub 2012 Oct 17.

17.

Assessment of HIV-1 patient recruitability in the Republic of Guinea-Bissau using African versus North American hematology and biochemistry reference intervals.

Gómez Román VR, Jensen SS, Leo-Hansen C, Jensen KJ, Janitzek CM, Rodrigues CM, Jespersen S, Katzenstein TL, Té Dda S, Fomsgaard A.

Clin Vaccine Immunol. 2012 Aug;19(8):1322-5. doi: 10.1128/CVI.00170-12. Epub 2012 Jun 6.

18.

Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.

Faria NR, Hodges-Mameletzis I, Silva JC, Rodés B, Erasmus S, Paolucci S, Ruelle J, Pieniazek D, Taveira N, Treviño A, Gonçalves MF, Jallow S, Xu L, Camacho RJ, Soriano V, Goubau P, de Sousa JD, Vandamme AM, Suchard MA, Lemey P.

J Gen Virol. 2012 Apr;93(Pt 4):889-99. doi: 10.1099/vir.0.038638-0. Epub 2011 Dec 21.

19.

Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjörnsson J, Månsson F, Andersson S, Norrgren H, Aaby P, Jansson M, Fenyö EM.

J Virol. 2012 Jan;86(2):961-71. doi: 10.1128/JVI.06315-11. Epub 2011 Nov 9.

20.

Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

de Silva TI, Aasa-Chapman M, Cotten M, Hué S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R.

J Virol. 2012 Jan;86(2):930-46. doi: 10.1128/JVI.06126-11. Epub 2011 Nov 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk